SGLT2 inhibitors were not associated with gastrointestinal cancers across 48 trials

Design

Systematic review and meta-analysis of randomised trials

Population

48 trials, 48,765 adults with type 2 diabetes

Primary outcome

Gastrointestinal neoplasms reported as adverse events

Effect

OR 1.10 (95% CI 0.84 to 1.44), I² = 0%

A systematic review pooled 48 randomised trials (48,765 people with type 2 diabetes) comparing SGLT2 inhibitors with placebo or active drugs, and extracted gastrointestinal neoplasms reported as adverse events.

The overall odds ratio was 1.10 (95% CI 0.84 to 1.44), with no heterogeneity. No site, from oesophagus to rectum, showed a significant association, and results did not differ by agent, age, BMI, HbA1c, duration or dose.

This is reassuring for patients who ask about cancer after reading about SGLT2 inhibitors. But about half the trials ran a year or less, cancers were not adjudicated, and events were few, so it cannot speak to long-term risk.

• Reassure patients that trial data show no gastrointestinal cancer excess
• Continue usual age-appropriate cancer screening
• Investigate alarm symptoms on their own merits, not as a drug effect

Why it matters

It answers a patient worry with trial data, while leaving long-term cancer risk genuinely unmeasured.

Don't overread it

Short follow-up and unadjudicated adverse-event reporting mean this is not proof of long-term oncological safety.

The statistics, in plain English

An odds ratio of 1.10 with an interval of 0.84 to 1.44 means the data fit anything from 16% fewer to 44% more reported GI neoplasms. I² of 0% means the trials agreed with each other, which helps, but consistent short trials can still all miss a cancer effect that takes years to appear.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.